Published 4 days ago • loading... • Updated 2 days ago

Results From Real-World, Long-Term Treatment Persistence with LEQEMBI® (Lecanemab-Irmb) in the United States Presented at AD/PD™ 2026

On March 19, 2026, ImmunoBrain presented Phase 1b data showing a favorable safety profile and biomarker signals concordant with neuronal protection.
Built on academic work, ImmunoBrain's approach uses IBC-Ab002, a fully human, Fc-modified anti-PD-L1 antibody designed for intermittent dosing to reduce autoimmune risk, supported by NIA and Alzheimer's Association grants.
The Phase 1b study enrolled 40 patients across the U.K., the Netherlands and Israel, with a mean follow-up of 350.9 days and dosing averaging 1.7 administrations per month at 16.4-day intervals.
ImmunoBrain is designing the next-phase trials incorporating cognitive endpoints, and Professor Catherine J. Mummery said 'There remains a significant unmet need for disease-modifying therapies that address the underlying biology of Alzheimer's disease'.
ImmunoBrain's scientific founders note the platform builds on more than 25 years of research to activate the peripheral immune system, and Professor Michal Schwartz, Ph.D., said 'We are very encouraged by these results and believe they pave the way for ImmunoBrain's next stage clinical study'.

Insights by Ground AI